Luspatercept and Lenalidomide (L2)

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
50 patients (estimated)
Sponsors
University of Miami
Collaborators
Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, Bristol Myers Squibb
Tags
Erythroid Maturation Agent (EMA), Immunomodulatory Drug (IMiD), Red Blood Cell Stimulant
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1604
NCT Identifier
NCT04539236

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.